A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus.

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2014

At a glance

  • Drugs AMG 557 (Primary)
  • Indications Cutaneous lupus erythematosus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 09 Jan 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 03 Oct 2012 Planned number of patients changed from 20 to 32 as reported by ClinicalTrials.gov.
    • 30 Apr 2012 Additional trial locations (Australia, Canada) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top